Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s traded shares stood at 2.08 million during the last session, with the company’s beta value hitting 1.36. At the close of trading, the stock’s price was $10.91, to imply a decrease of -5.87% or -$0.68 in intraday trading. The AVDL share’s 52-week high remains $19.09, putting it -74.98% down since that peak but still an impressive 4.77% since price per share fell to its 52-week low of $10.39. The company has a valuation of $1.05B, with an average of 1.99 million shares in intraday trading volume over the past 10 days and average of 1.07 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Avadel Pharmaceuticals plc (AVDL), translating to a mean rating of 1.00. Of 8 analyst(s) looking at the stock, 0 analyst(s) give AVDL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
After registering a -5.87% downside in the last session, Avadel Pharmaceuticals plc (AVDL) has traded red over the past five days. The 5-day price performance for the stock is -31.56%, and -21.62% over 30 days. With these gigs, the year-to-date price performance is -22.73%. Short interest in Avadel Pharmaceuticals plc (NASDAQ:AVDL) saw shorts transact 9.45 million shares and set a 11.17 days time to cover.
The extremes give us $9 and $30 for target low and target high price respectively. As such, AVDL has been trading -174.98% off suggested target high and 17.51% from its likely low.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Looking at statistics comparing Avadel Pharmaceuticals plc share performance against respective industry, we note that the company has outperformed competitors. Avadel Pharmaceuticals plc (AVDL) shares are -29.57% down over the last 6 months, with its year-to-date growth rate higher than industry average at 75.50% against 16.20%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 4.78% for the past 5-year period. While 2024 is set for a 76.06% return in earnings, projections for the next 5 years are at 15.00% annually.
AVDL Dividends
Avadel Pharmaceuticals plc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
Avadel Pharmaceuticals plc insiders hold 4.77% of total outstanding shares, with institutional holders owning 79.87% of the shares at 83.87% float percentage. In total, 79.87% institutions holds shares in the company, led by VIVO CAPITAL, LLC. As of 2024-06-30, the company held over 3.97 million shares (or 4.332% of shares), all amounting to roughly $55.85 million.
The next major institution holding the largest number of shares is TRI LOCUM PARTNERS LP with 1.19 million shares, or about 1.2973% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $16.72 million.
